Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have earned a consensus recommendation of “Buy” from the nine ratings firms that are covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $12.6250.

CATX has been the topic of a number of recent research reports. UBS Group lifted their price target on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. B. Riley Financial lifted their price target on Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Royal Bank Of Canada cut their price target on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 17th. HC Wainwright lifted their price target on Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, May 5th.

Perspective Therapeutics Price Performance

Shares of CATX stock opened at $3.04 on Monday. The business’s 50-day moving average price is $3.65 and its 200-day moving average price is $3.83. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%.The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.16 million. Analysts predict that Perspective Therapeutics will post -1.11 earnings per share for the current year.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. lifted its stake in shares of Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after acquiring an additional 5,475 shares during the period. Aigen Investment Management LP acquired a new position in shares of Perspective Therapeutics in the fourth quarter worth approximately $28,000. nVerses Capital LLC acquired a new position in shares of Perspective Therapeutics in the fourth quarter worth approximately $31,000. Abel Hall LLC acquired a new position in shares of Perspective Therapeutics in the first quarter worth approximately $49,000. Finally, Engineers Gate Manager LP acquired a new position in shares of Perspective Therapeutics in the fourth quarter worth approximately $35,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.